Search
News Chat
Login
Search
Top
For You
Business
Crypto
Culture
Environment
Politics
Science
Sports
Tech
Video Games
World
Cytokinetics News
CYTK
CYTOKINETICS INC
54.84
+0.26%
CYTK
CYTOKINETICS INC
54.84
+0.26%
Prediction markets for Cytokinetics
Prediction markets for Cytokinetics
Will Cytokinetics agree to be acquired by the end of 2024?
Dec 17, 6:49 AM
Jan 2, 4:59 AM
54.51%
chance
5
99
Option
Votes
NO
YES
152
106
Articles
Latest stories
Cytokinetics, Royalty Pharma Announce $575M Funding for Aficamten; 9.8M Shares Offered, 14.9% Pre-Market Drop
Authors
10
1 month
Bio
Science
Cytokinetics Sells Heart Drug Share to Royalty Pharma for $575 Million, Buyout Hopes Dim
Authors
8
1 month
Bio
Science
Cytokinetics Secures $575M Deal with Royalty Pharma, Plans New Phase III Trials for Aficamten and Omecamtiv
Authors
15
1 month
Bio
Science
Cytokinetics' Heart Drug Shows Promise, CEO Robert Blum Addresses Acquisition Speculation
Authors
5
2 months
Bio
Science
Cytokinetics' aficamten drug poised to challenge Bristol Myers Squibb's heart treatment with similar efficacy and safety, gearing up for potential launch
Authors
11
2 months
Bio
Science
Cytokinetics to Pitch Aficamten, Competing with BMS' $13.1B Camzyos
Authors
9
2 months
Bio
Science
Novavax Misses Estimates, Q4 Revenues $291M, FY'23 Revenue $1B
Authors
11
4 months
Economics
Business
Cytokinetics ($CYTK) Reports Q4 2023 Results Amid CEO's Denial of M&A Speculation
Authors
9
4 months
Bio
Science
Cytokinetics Faces Sentiment Shift on Biotwitter, CEO Denies Novartis Acquisition Speculation
Authors
5
4 months
Bio
Science
Cytokinetics' Aficamten Succeeds in Study, Spurs Takeover Speculation
Authors
9
6 months
Economics
Business
Previous
Next